A detailed history of Amalgamated Bank transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Amalgamated Bank holds 602 shares of JANX stock, worth $25,217. This represents 0.0% of its overall portfolio holdings.

Number of Shares
602
Previous 1,587 62.07%
Holding current value
$25,217
Previous $17,000 35.29%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 23, 2024

SELL
$7.93 - $49.75 $7,811 - $49,003
-985 Reduced 62.07%
602 $23,000
Q4 2023

Feb 06, 2024

SELL
$5.85 - $11.7 $1,047 - $2,094
-179 Reduced 10.14%
1,587 $17,000
Q2 2023

Aug 11, 2023

SELL
$11.08 - $15.92 $199 - $286
-18 Reduced 1.01%
1,766 $20,000
Q1 2023

May 02, 2023

SELL
$11.25 - $22.21 $4,477 - $8,839
-398 Reduced 18.24%
1,784 $22,000
Q2 2022

Aug 15, 2022

BUY
$9.52 - $15.65 $2,418 - $3,975
254 Added 13.17%
2,182 $27,000
Q1 2022

Jun 30, 2022

BUY
$13.24 - $20.24 $25,526 - $39,022
1,928 New
1,928 $28,000

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $1.75B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Amalgamated Bank Portfolio

Follow Amalgamated Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Amalgamated Bank, based on Form 13F filings with the SEC.

News

Stay updated on Amalgamated Bank with notifications on news.